A1 adenosine receptor agonists and antagonists offer potential therapeutic opportunities for cardiovascular diseases by providing cardioprotective and renoprotective effects.
This review highlights the molecular mechanisms and therapeutic potential of targeting the A1 adenosine receptor for the management of cardiovascular diseases.
Adenosine serves as a critical homeostatic regulator, exerting influence over physiological and pathological conditions in the cardiovascular system. During cellular stress, increased extracellular adenosine levels have been implicated in conferring cardioprotective effects through the activation of adenosine receptors with the A 1 adenosine receptor subtype showing the highest expression in the heart. A 1 adenosine receptor stimulation inhibits adenylyl cyclase activity via heterotrimeric G i proteins, leading to the activation of distinct downstream effectors involved in cardiovascular homeostasis. While the comprehensive characterization of the pharmacological functions and intracellular signaling pathways associated with the A 1 adenosine receptor subtype is still ongoing, this receptor is widely recognized as a crucial pharmacological target for the treatment of various states of cardiovascular diseases (CVDs). In this review, we focus on elucidating signal transduction of A 1 adenosine receptor, particularly G i protein-dependent and -independent pathways, and their relevance to cardiovascular protective effects as well as pathological consequences during cellular and tissue stresses in the cardiovascular system. Additionally, we provide comprehensive updates and detailed insights into a range of A 1 adenosine receptor agonists and antagonists, detailing their development and evaluation through preclinical and clinical studies with a specific focus on their potential for the management of CVDs, especially heart diseases. • A 1 adenosine receptors play a key role in cardiovascular diseases (CVDs). • Activation of A 1 adenosine receptor provides cardioprotective effects. • A 1 adenosine receptor engages in both G protein-dependent and independent signaling. • Full and partial agonists of A 1 adenosine receptor are developed for CVD treatment. • Antagonists of A 1 adenosine receptor benefit CVDs through renoprotective effect.
Parichatikanond et al. (Tue,) conducted a review in Cardiovascular diseases. A1 adenosine receptor agonists and antagonists was evaluated. A1 adenosine receptor agonists and antagonists offer potential therapeutic opportunities for cardiovascular diseases by providing cardioprotective and renoprotective effects.